astrazeneca_sign_sky

FDA approves AZ’s Lokelma for hyperkalaemia

pharmafile | May 21, 2018 | News story | Sales and Marketing AstraZeneca, FDA, Lokelma, hyperkalaemia, pharma 

The FDA has revealed its decision to approve AstraZeneca’s oral potassium-removing agent Lokelma (sodium zirconium cyclosilicate) for the treatment of hyperkalaemia.

The decision was based on the drug’s strong showing in Phase 3 trials, meaning it will now be available for use in the US.

Hyperkalaemia is a condition characterised by increased levels of potassium in the blood and can lead to cardiac arrest or even death. In severe cases, mortality rates stand at around 30% if not treated quickly. Risk of developing the disease rises significantly in patients with chronic kidney disease (CKD) or those who take common medications for heart failure such as renin-angiotensin-aldosterone system (RAAS) inhibitors.

Advertisement

“We are pleased by today’s FDA approval of Lokelma as it enables us to help address a long-standing clinical need with a new medicine that offers rapid and sustained treatment for adults with hyperkalaemia,” commented Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca. “The consequences of hyperkalaemia can be very serious and it’s reassuring for treating physicians that Lokelma has demonstrated lowering of potassium levels in patients with chronic kidney disease, heart failure, diabetes and those taking RAAS inhibitors.”

Matt Fellows

Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification

Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …

The Gateway to Local Adoption Series

Latest content